The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML | Oncogene
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression - ScienceDirect
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
JQ1 - Wikipedia
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma | EMBO Molecular Medicine
Cancers | Free Full-Text | Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications | HTML
Cancers | Free Full-Text | Role of BET Inhibitors in Triple Negative Breast Cancers | HTML
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy | Future Science OA
Clinical trials evaluating BET inhibitors with results in patients with... | Download Scientific Diagram
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Targeting MYC dependence in cancer by inhibiting BET bromodomains | PNAS
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer - ScienceDirect
Bromodomain inhibitors in clinical trials | Download Table
Sierra Signs Exclusive Deal with AstraZeneca for Potent BRD4 BET Inhibitor | BioSpace
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Next-generation epigenetic inhibitors
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs - RSC Advances (RSC Publishing) DOI:10.1039/D0RA07971E
